Kiora Pharmaceuticals, Inc. (KPRX) — Analyst outlook / Analyst consensus target is. Based on 3 analyst ratings, the consensus is bullish — 3 Buy.
Analysts estimate Earnings Per Share (EPS) of $0.87 and revenue of $0.02B for the next fiscal year.
Earnings Per Share (EPS) track record: 2024: actual $0.93 vs est $0.87 (beat +7.5%). 2025: actual $-2.60 vs est $-1.71 (missed -52%). Analyst accuracy: 79%.
KPRX Analyst Ratings
Buy
Based on 3 analysts giving stock ratings to Kiora Pharmaceuticals, Inc. in the past 3 months
EPS Estimates — KPRX
79%
Analyst Accuracy
Fair
2 years compared
Actual vs Estimate
2024
Actual $0.93
vs Est $0.87
▲ 7.0% off
2025
Actual –$2.60
vs Est –$1.71
▼ 34.2% off
Profitability Outlook
Company has mixed profitability — some years profitable, some at a loss. Analysts expect the company to turn profitable.
Revenue Estimates — KPRX
95%
Analyst Accuracy
Accurate
1 year compared
Actual vs Estimate
2024
Actual $0.016B
vs Est $0.017B
▼ 4.6% off
Revenue Trend
Revenue has declined over the period shown. Analysts expect stable revenue going forward.
